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Abstract
Background: To evaluate clinical outcomes of stereotactic body radiotherapy (SBRT) for localized primary and
oligometastatic lung tumors by assessing efficacy and safety of 5 regimens of varying fraction size and number.
Methods: One-hundred patients with primary lung cancer (n = 69) or oligometastatic lung tumors (n = 31), who
underwent SBRT between May 2003 and August 2010, were included. The median age was 75 years (range, 45–88).
Of them, 98 were judged to have medically inoperable disease, predominantly due to chronic illness or advanced
age. SBRT was performed using 3 coplanar and 3 non-coplanar fixed beams with a standard linear accelerator.
Fraction sizes were escalated by 1 Gy, and number of fractions given was decreased by 1 for every 20 included
patients. Total target doses were between 50 and 56 Gy, administered as 5–9 fractions. The prescribed dose was
defined at the isocenter, and median overall treatment duration was 10 days (range, 5–22).
Results: The median follow-up was 51.1 months for survivors. The 3-year local recurrence rates for primary lung
cancer and oligometastasis was 6 % and 3 %, respectively. The 3-year local recurrence rates for tumor sizes ≤3 cm
and >3 cm were 3 % and 14 %, respectively (p = 0.124). Additionally, other factors (fraction size, total target dose,
and BED10) were not significant predictors of local control. Radiation pneumonia (≥ grade 2) was observed in 2
patients. Radiation-induced rib fractures were observed in 22 patients. Other late adverse events of greater than
grade 2 were not observed.
Conclusion: Within this dataset, we did not observe a dose response in BED10 values between 86.4 and 102.6 Gy.
SBRT with doses between 50 and 56 Gy, administered over 5–9 fractions achieved acceptable tumor control
without severe complications.
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Background
The use of stereotactic body radiotherapy (SBRT) for the
treatment of localized lung tumors, including early-stage
non-small cell lung cancer and lung metastases, was in-
troduced in the mid-1990s in Japan and Western coun-
tries [1–8]. Although SBRT is generally performed with
higher fraction sizes, the optimal fractionation schedule
for SBRT remains unclear. SBRT is associated with ex-
cellent local control and minimal toxicity; however, fatal
pulmonary bleeding following radiotherapy has been re-
ported with the use of hypofractionated regimens for
centrally located tumors [9]. Although a fraction size of
12 Gy is widely used in Japan [10], we started our dose
escalation study of SBRT for localized lung tumor with a
fraction size of 6 Gy from May 2003 in order to avoid
serious late complications. We previously published our
initial clinical experience of SBRT in patients with early-
stage non-small cell lung cancer and lung metastasis,
using a total dose of 54 Gy administered in 9 fractions
[11], and has since performed a dose escalation study
with increases in fraction size of 1 Gy.
The purpose of the present study was to evaluate clin-
ical outcomes following stereotactic body radiotherapy
for localized primary and metastatic lung tumor and as-
sess the efficacy and safety of 5 regimens with varying
fraction size and number at total doses of 50–56 Gy.
Methods
Eligibility criteria
The initial eligibility criteria for this study were as follows:
(1) lung cancer (T1–2N0M0) or lung metastases without
active primary cancer; (2) maximum tumor diameter < 50
mm; (3) visible disease by fluoroscopy; (4) performance
status score of ≤ 2, according to the Eastern Cooperative
Oncology Group (ECOG) performance scale.
This study was approved by the institutional review
board of Hirosaki University School of Medicine, and
written informed consent was obtained from all patients.
Patient and tumor characteristics
A total of 100 patients with primary or oligometastatic
lung tumor underwent SBRT between May 2003 and
August 2010 at our institution. All tumors were periph-
erally located, and all patients underwent appropriate
staging studies to determine clinical diagnoses and stage.
Stage IA lung cancer, stage IB lung cancer, and oligome-
tastatic lung tumors were identified in 58, 11, and 31 pa-
tients, respectively. The primary sites of oligometastatic
lung tumors in patients were as follows: lung cancer, 21;
gastrointestinal cancer, 5; head and neck cancer, 3; and
gynecologic cancer, 2 patients. Group A comprised pa-
tients with histopathological or cytological confirmation
of disease based on the results of biopsy or cytological
examination. In cases without histopathological or
cytological confirmation (Group B), increases in max-
imum tumor diameter or standardized tumoral uptake on
fluorodeoxyglucose positron emission tomography (FDG-
PET CT) were required. The median patient age was 75
years (range, 45–88). Of the 100 patients, 98 (98 %) were
judged to have medically inoperable disease by a
multidisciplinary team of thoracic surgeons, pulmo-
nologists, and radiation oncologists, predominantly on
the basis of chronic illness or advanced age. Two pa-
tients judged to have medically operable disease re-
fused surgery. Patient and tumor characteristics are
summarized in Table 1.
Treatment procedure
All patients raised both upper arms and were immobi-
lized using a thermo-shell (ALCARE Co., Ltd., Tokyo,
Japan) and a custom-made MoldCare headrest
(ALCARE Co., Ltd., Tokyo, Japan) [11, 12]. Following
patient immobilization, tumoral movement due to res-
piration of no more than 10 mm was confirmed, using
an X-ray simulator (Toshiba Medical Systems Co., Ltd.,
Tokyo, Japan). Planning computed tomography (CT)
was performed without breath-holding by a CT-
simulator (Aquilion, Toshiba Medical Systems Co., Ltd.,
Table 1 Patient and tumor characteristics
Group A Group B
Patients (n) 86 14








Primary lung cancer 66 3
Metastasis 20 11
Tumor diameter
≤3 cm 73 13
>3 cm 13 1
Histological type
Adenocarcinoma 58
Squamous cell carcinoma 26
Other 2
Increasing tumor size 14
SUV positive 6
Abbreviations: SUV Standardized uptake value
Group A comprised patients with histopathological or cytological confirmation
of disease based on the results of biopsy or cytological examination. Group B
comprised patients without histopathological or cytological confirmation
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Tokyo, Japan) with 2.0 mm thickness for the identifica-
tion of tumor location and calculation of treatment
doses. Where tumoral movement due to respiration was
10 mm or more, planning CT was performed with
breath-holding using a respiratory-monitoring apparatus
(Abches, APEX Medical Inc., Tokyo, Japan). After Sep-
tember 2008, CT was performed using a breathing
adapted technique with thickness of 2.5 mm by 4-
dimensional PET/CT (Discovery ST Elite, GE Health-
care, Tokyo, Japan) and a real-time position manage-
ment system (RPM gating system, Varian Medical
Systems, Tokyo, Japan). A three-dimensional (3D) radio-
therapy treatment-planning (RTP) machine (XiO version
4.1.1, CMS Japan, Tokyo, Japan) was used for dose cal-
culation. Outlines of target and normal tissues (total
lung, spinal cord, vertebrae) were drawn in all patients.
Target margins were calculated as follows: the clinical
target volume (CTV) was equal to the gross tumor vol-
ume (GTV) delineated on CT images displayed with a
window level of −300 Hounsfield units (HU) and a win-
dow width of 1700 HU; the internal target volume (ITV)
was calculated as CTV plus a 5–10-mm margin based
on tumor movement, determined using an X-ray simula-
tor; the planning target volume (PTV) was calculated as
CTV plus with a 5-mm margin in all directions. A leaf
margin of 5 mm around the PTV was also calculated.
Dose calculations were initially performed in accord-
ance with the Clarkson’s method and the superposition
method by 3D-RTP corrected for inhomogeneity. Radio-
therapy was performed on 100 patients with fixed mul-
tiple coplanar and non-coplanar conformal beams by a
10-MV standard linear accelerator with EXL-20TP (Mit-
subishi Electric Co., Ltd., Tokyo). Initially, 4 beams were
used, and this was subsequently increased to 6 to im-
prove dose distribution. The number of beams used was
as follows: 4 in 1 patient, 5 in 7 patients, and 6 in the
remaining 92 patients. The current beam arrangement
consists of 3 non-coplanar oblique anterior beams in
addition to 2 coplanar oblique posterior beams with 1
coplanar lateral beam. Fractionation was initially per-
formed at a total dose of 54 Gy, administered in 9 frac-
tions. The prescribed dose was defined as the isocenter.
Fraction sizes were increased by 1 Gy, and fraction num-
bers were decreased by 1 fraction, for every 20 subse-
quent patients, thereafter. To compare the anti-tumor
effects of various fractionation schedules, a biologically ef-
fective dose (BED) was utilized based on a linear-
quadratic (LQ) model [13]. BED10 was defined as nd [1 +
d / (α/β)], where n and d represent the number of frac-
tions and fraction size, respectively, and α/β is assumed to
be 10 Gy for tumor. The value of BED10 in our subjects
were as follows: 86.4 Gy for a total dose of 54 Gy adminis-
tered in 9 fractions; 95.2 Gy for 56 Gy administered in 8
fractions; 100.8 Gy for 56 Gy administered in 7 fractions;
102.6 Gy for 54 Gy administered in 6 fractions; and 100
Gy for 50 Gy administered in 5 fractions. The median
overall treatment duration was 10 days (range, 5–22).
Tumor location was confirmed prior to each administra-
tion with an electronic portal-imaging device (EPID). In
the present study, an EPID-based setup was performed on
bony anatomy.
Follow-up and statistics
The endpoints used for evaluation were local recurrence
rates and toxicity. Follow-up images were obtained at 3–
6-month intervals and were used to assess tumor con-
trol. Patients were also periodically monitored by routine
medical examination, during and after treatment. Local
recurrence was diagnosed on the basis of enlargement of
the local tumor on follow-up CT that continued for at
least 6 months. FDG-PET and/or histologic confirmation
was recommended when local recurrence was suspected,
but this was not mandatory. Toxicities were assessed ac-
cording to National Cancer Institute-Common Termin-
ology Criteria for Adverse Events ver 4.0 (CTCAE).
All statistical analyses were performed by a competing
risk analysis using R version 2.8.1 (http://www.nature.-
com/bmt/journal/v40/n4/full/1705727a.html). Actuarial
curves were calculated by “CumIncidence.R”, according
to the interval from the first date of treatment. Differ-
ences in distributions were evaluated using the log-rank
test. Differences were regarded as statistically significant
when p-value was <0.05.
Results
The median follow-up period for all patients and survi-
vors were 44.8 and 51.1 months, respectively. Totally, 30
of 100 patients died during the follow-up period of 3–
128 months. Causes of death in these patients were
other diseases in 17 patients and disease progression in
13 patients. Of the 100 patients, 70 patients were alive at
the last follow-up session. The actuarial 3- and 5-year
overall survival rates for all patients were 77.9 % and
68.5 %, respectively.
Local recurrence
Of the 100 patients enrolled in this study, 9 (9 %) devel-
oped local recurrence within the follow-up period. The
time to local recurrence varied between 12 and 48
months (median, 17.9). Seven of the 9 instances of local
recurrence occurred within 36 months. Two of the 9 pa-
tients with local failure had additional metastases (Fig. 1).
Overall, 40 patients developed progressive disease during
the follow-up period and 27 patients (27 %) distant fail-
ure. Of the 27 patients with distant failure, 19 (70 %)
had lung metastases outside of the radiation field.
The 3-year local recurrence rates for primary lung can-
cer and oligometastases were 6 % and 3 % (P = 0.428),
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respectively, as shown in Fig. 2. The 3-year local recur-
rence rates for tumor size less than 3 cm and greater than
3 cm were 3 % and 14 %, respectively (p = 0.124), as
shown in Fig. 3a. The BED10 was not found to be a pre-
dictor of local recurrence, as shown in Fig. 3b. A summary
of the 3-year local control rates according to each SBRT
fractionation schedule is shown in Table 2. Other factors,
such as fraction size and total dose, were not found to be
predictors of local control.
Toxicity
Individual treatments took approximately 30 min, re-
gardless of fractionation schedule. All patients were suc-
cessfully treated without acute toxicities. The toxicities
are summarized in Table 3. Grade 1 and 2 radiation
pneumonitis was identified in 70 and 2 patients, respect-
ively. In both the grade 2 pneumonitis patients, toxicity
occurred 6 months after SBRT; hence, oral steroid ther-
apy was administered, and pneumonitis resolved within
6 months.
Grade 1 radiation-induced rib fractures were identified
in 22 patients. Grade 1 radiation-induced rib fractures
occurred between 12 and 48 months (median, 30) after
SBRT. No late adverse events greater than grade 3 were
observed in the present study.
Discussion
The results of this study indicate SBRT at total doses be-
tween 50 and 56 Gy administered in 5–9 fractions was
feasible for primary lung cancer and oligometastatic lung
tumors. In our study, grade 2 pulmonary toxicity was
observed in 2 patients with an overall 3-year local con-
trol rate of over 90 %, equivalent to rates previously re-
ported for SBRT [1–8]. Additionally, no significant
difference was observed in BED10 values between 86.4
and 102.6 Gy.
Nagata Y. et al. [10] evaluated the current status of
SBRT in Japan and reported fractionation schedules. Ac-
cording to their survey, the commonest schedules for
primary lung cancer were 48 Gy administered in 4 frac-
tions (22 institutions), followed by 50 Gy administered
in 5 fractions (11 institutions), and 60 Gy administered
in 8 fractions (4 institutions). The use of 48 Gy adminis-
tered in 4 fractions may be the commonest schedule in
Japan, as a result of the impact of a recent Japanese
Phase II clinical trial (JCOG0403) [14]. However, various
fractionation schedules are currently being performed in
many other institutions in Japan, as there is currently a
lack of consensus regarding the optimal fractionation
schedules for SBRT. Therefore, BED values for tumoral
and normal tissues have been utilized to compare the ef-
ficacy of various fractionation schedules, with many in-
vestigators reporting the utility of BED.
There have been several reports of the correlation be-
tween BED10 and local control. Onishi et al. [15] evaluated
the clinical outcomes following stereotactic hypofractio-
nated high-dose irradiation of stage I non-small cell lung
carcinoma and found local control rates were better with
BED10 ≥ 100 Gy, compared with BED10 < 100 Gy. Similar
findings regarding the importance of BED10 on local con-
trol have been reported by Nagata Y. et al. [16]. BED10 ap-
pears to be useful in comparing the efficacy of treatment
protocols with varying fraction sizes and total doses. On
the other hand, Shibamoto Y, et al. [17] highlighted issues
with the use of the LQ model and BED for estimating the
efficacy of radiation schedules in SBRT. The LQ model has
utility in the conversion of relatively low radiation doses
used in conventional radiotherapy; however, it has been
suggested that the LQ model is not applicable to higher
daily doses or smaller fraction numbers [18]. In our study,









Fig. 1 Failure patterns of the 40 disease progressions that were
encountered during follow-up of the 100 patients included in
this study
Fig. 2 Estimated cumulative incidence curves of local recurrence rates
after SBRT, according to clinical diagnosis
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Gy was equivalent to the rate of over 95 % for BED10 ≥
100 Gy. This result indicates BED has no usefulness in es-
timating the efficacy of radiation schedules for SBRT.
However, alternative mathematical models for estimating
the efficacy of radiation schedules for SBRT are yet to be
developed. Therefore, further research is necessary, focus-
ing on the development of alternative mathematical
models for SBRT.
Aside for the issues associated with use of the LQ
model and BED, the higher local control rate in 40 pa-
tients with BED less than 100 Gy remains incompletely
understood. In our study, despite 22.5 % (9/40) of tu-
mors in the low-BED group (<100 Gy) with a maximum
diameter of 3 cm or more, the 3-year local control rate
was over 90 %. Additionally, in our study, the 3-year
local control rate using competing risk analysis of 86 %
for T2 tumors (≥3 cm) was almost equivalent to previ-
ous clinical studies that reported local control rates of
70 %–78 % for T2 tumors, following the use of higher
fraction sizes (greater than 10 Gy) [19–22]. Fraction
sizes were smaller, overall treatment times were longer,
and fraction numbers were larger in the low-BED group.
From a radiobiological standpoint, these findings suggest
that during SBRT, prolonged treatment periods and larger
fraction numbers may have a positive effect on local con-
trol through reoxygenation or redistribution of cancer
cells during treatment. A large amount of evidence sug-
gests tumoral reoxygenation occurs 24–72 h following
irradiation [23–26]. The redistribution of cancer cells is
believed to play an important role in enhancing the thera-
peutic effect of irradiation as a result of reoxygenation
[27]. In other words, our study indicates increasing the
number of fractions and extending the overall treatment
duration of fractionation schedules are important for local
control in addition to increasing the fraction size. How-
ever, medical expenses and the balance between local con-
trol and side effects are also important considerations for
the development of optimal fractionation schedules. Jain
S, et al. [28] conducted a randomized study in patients
treated with four fractions of lung SBRT delivered over 4
or 11 days locking at acute toxicity and quality of life and
concluded that grade 2 or higher acute toxicity was more
common in the 4-day group. Although, local control rates
for 4- or 11-day groups are not reported, long treatment
times in Jain’s study is very interesting for future direction
of SBRT schedules.
Dose/volume-effect relationships in SBRT for primary
and secondary lung tumors have been discussed in re-
cent papers. Guckenberger M, et al. [29] conducted a
retrospective multi-institutional study in 399 patients
with stage I non-small cell lung cancer and 397 patients
with 525 lung metastases and concluded that the dose–
response relationships for local tumor control in SBRT
were not different between lung metastases of various
primary cancer sites and between primary non-small cell
lung cancers and lung metastases. Suzuki O, et al. [30]
Fig. 3 Estimated cumulative incidence curves of local recurrence rates after SBRT, according to tumor size (a) and BED10 (b)
Table 2 Three-year local control rates based on fractionation schedule
Fraction size Total dose BED10 Mean OTT (95 % CI) Tumor size (n) 3-year LC
(Gy) (Gy) (Gy) (days) ≤3 cm >3 cm (%)
6 54 86.4 14.7 (13.2–16.1) 12 8 90
7 56 95.2 11.7 (11.1–12.4) 19 1 95
8 56 100.8 10.3 (9.6–11.0) 19 1 95
9 54 102.6 8.4 (8.0–8.8) 18 2 95
10 50 100.0 7.1 (6.8–7.3) 18 2 100
Abbreviations: BED Biologically effective dose, OTT Overall treatment time, LC Local control
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reported a dose-volume-response analysis in SBRT for
early lung cancer among Japan and Western countries.
The BED10 at PTV periphery was 102 Gy in Western
countries and 83 Gy in Japan. The local control was bet-
ter in Western countries for larger tumors but was simi-
lar for smaller tumors. The dose was prescribed at the
isocenter in our study; dose–response relationship was
not observed in tumor size and primary and oligo-
metastatic lung tumors.
The current study had the following limitations. First,
the study was performed without upfront power and
sample size calculations. Second, analysing dose but not
tumor size as risk factor for local recurrence was the pri-
mary intent of the study, and additionally, most likely by
chance, tumors had been larger in the first phase of the
study (at the 6 Gy level). Third, the dose was prescribed
at the isocenter, and the aperture was set at 5 mm be-
yond PTV; the peripheral dose for PTV was different to
Western approaches [30]. Fourth, all tumors included in
this study were peripherally located, meaning the efficacy
of these fractionation schedules for the treatment of cen-
tral lesions remains unclear. Fifth, the dose calculation
was changed during the study period; this possibly af-
fected the administered doses. Finally, patient and tumor
characteristic differed for each fractionation schedule be-
cause this was not a randomized study.
This study, however, provides a novel perspective on
future directions for the development of optimal frac-
tionation schedules in stereotactic body radiotherapy for
patients with primary lung cancer or oligometastatic
lung tumor.
Conclusion
Regardless of fractionation schedule, stereotactic body
radiotherapy with total doses between 50 and 56 Gy ad-
ministered over 5–9 fractions achieved acceptable tumor
control without severe complications. For stage IB pri-
mary lung cancer, however, more intensive regimen ap-
pear necessary to achieve local control. From a
radiobiological standpoint, increasing the number of
fractions and extending the overall treatment duration
of fractionation schedules may also be important factors
that influence local control.
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